These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 12817211)

  • 1. Treatment of primary HIV infection.
    Daar ES
    MedGenMed; 2002 Nov; 4(4):15. PubMed ID: 12817211
    [No Abstract]   [Full Text] [Related]  

  • 2. Intermittent therapy for the treatment of chronic HIV infection.
    Ananworanich J; Hirschel B
    AIDS; 2007 Jan; 21(2):123-34. PubMed ID: 17197802
    [No Abstract]   [Full Text] [Related]  

  • 3. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Timing of highly active antiretroviral therapy and chemotherapy for Kaposi's sarcoma in patients with HIV infection.
    Loke WC; Spittle MF; Mitchell S; Kulasegaram R
    Int J STD AIDS; 2006 Aug; 17(8):565-6. PubMed ID: 16925908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary HIV-1 infection: to treat or not to treat?
    Blankson JN
    AIDS Read; 2005 May; 15(5):245-6, 249-51. PubMed ID: 15900634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV, atherosclerosis and inflammation: implications for treatment.
    Chan W; Sviridov D; Dart AM
    J HIV Ther; 2009 Nov; 14(3):61-8. PubMed ID: 20218241
    [No Abstract]   [Full Text] [Related]  

  • 7. Editorial comment: treatment of acute HIV infection--uncertainties about best practice.
    Kassutto S; Rosenberg ES
    AIDS Read; 2005 May; 15(5):250-1. PubMed ID: 15900635
    [No Abstract]   [Full Text] [Related]  

  • 8. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection.
    Bekker V; Scherpbier H; Pajkrt D; Jurriaans S; Zaaijer H; Kuijpers TW
    Pediatrics; 2006 Aug; 118(2):e315-22. PubMed ID: 16847077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: Pediatric Spectrum of HIV Disease, 1989-2004.
    Schulte J; Dominguez K; Sukalac T; Bohannon B; Fowler MG;
    Pediatrics; 2007 Apr; 119(4):e900-6. PubMed ID: 17353299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained viral suppression and immune recovery in HIV type 1-infected children after 4 years of highly active antiretroviral therapy.
    Fraaij PL; Verweel G; van Rossum AM; van Lochem EG; Schutten M; Weemaes CM; Hartwig NG; Burger DM; de Groot R
    Clin Infect Dis; 2005 Feb; 40(4):604-8. PubMed ID: 15712085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Starting highly active antiretroviral therapy: why, when and response to HAART.
    Mocroft A; Lundgren JD
    J Antimicrob Chemother; 2004 Jul; 54(1):10-3. PubMed ID: 15163656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune-based therapy shows promise.
    AIDS Patient Care STDS; 2005 Jun; 19(6):415. PubMed ID: 16041868
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunologic and clinical responses to highly active antiretroviral therapy in patients with HIV infection aged >50 years.
    Cuzin L; Delpierre C; Gerard S; Massip P; Marchou B
    Clin Infect Dis; 2007 Sep; 45(5):654-7. PubMed ID: 17683004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status.
    Kwara A; Flanigan TP; Carter EJ
    Int J Tuberc Lung Dis; 2005 Mar; 9(3):248-57. PubMed ID: 15786886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Avoiding antiretroviral-associated cytopenias.
    Nassiri R
    J Am Osteopath Assoc; 2006 Mar; 106(3):111-2. PubMed ID: 16585370
    [No Abstract]   [Full Text] [Related]  

  • 16. HIV/AIDS: the management of treatment-experienced HIV-infected patients: new drugs and drug combinations.
    Wilson LE; Gallant JE
    Clin Infect Dis; 2009 Jan; 48(2):214-21. PubMed ID: 19072245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Earlier initiation of highly active antiretroviral therapy does not protect against the deleterious effects of non-adherence.
    Wood E; Hogg RS; Yip B; Harrigan PR; Montaner JS
    AIDS; 2004 Dec; 18(18):2432-4. PubMed ID: 15622322
    [No Abstract]   [Full Text] [Related]  

  • 18. Neurodevelopmental functioning in HIV-infected infants and young children before and after the introduction of protease inhibitor-based highly active antiretroviral therapy.
    Lindsey JC; Malee KM; Brouwers P; Hughes MD;
    Pediatrics; 2007 Mar; 119(3):e681-93. PubMed ID: 17296781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age-related immune reconstitution during highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children.
    van Rossum AM; de Groot R
    Pediatr Infect Dis J; 2003 Oct; 22(10):934; author reply 934-5. PubMed ID: 14551497
    [No Abstract]   [Full Text] [Related]  

  • 20. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy.
    Pozniak A; Gazzard B; Anderson J; Babiker A; Churchill D; Collins S; Fisher M; Johnson M; Khoo S; Leen C; Loveday C; Moyle G; Nelson M; Peter B; Phillips A; Pillay D; Wilkins E; Williams I; Youle M;
    HIV Med; 2003 Oct; 4 Suppl 1():1-41. PubMed ID: 14511246
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.